Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
Dillon
Richard
R
Department of Haematology, Hinchingbrooke Hospital, Huntingdon.
Hirschfield
Gideon M
GM
Allison
Michael E D
ME
Rege
Kanchan P
KP
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D017114:Liver Failure, Acute / Q000139:chemically induced*; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D019259:Lamivudine; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone